Aims and Scope
Instructions for Authors
Instructions for Reviewers
Ahead of Print
Most Read Articles
Most Cited Articles
Korean J Intern Med Search
> Browse Articles > Korean J Intern Med Search
Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma
Dae Sik Kim, Eun Sang Yu, Ka-Won Kang, Se Ryeon Lee, Yong Park, Hwa Jung Sung, Chul Won Choi, Byung Soo Kim
Korean J Intern Med.
2017;32(4):711-721. Published online November 4, 2016
Cited By 2
Background/Aims: The aims of this study were to identify the value of inflammatory markers as pretreatment prognostic factors for patients with multiple myeloma (MM) and to estimate the value of a prognostic index including these markers at diagnosis. Methods: A total of 273 newly diagnosed MM pati..
Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
Se Ryeon Lee, Hojoon Choi, Byung Hyun Lee, Ka-Won Kang, Eun Sang Yu, Dae Sik Kim, Yong Park, Chul Won Choi, Byung Soo Kim, Hwa Jung Sung
Received April 18, 2018 Accepted May 9, 2018 Published online October 26, 2018
[Epub ahead of print]
Background/Aims: Bortezomib plus melphalan-prednisone (VMP) is a standard treatment for multiple myeloma, particularly for patients who are ineligible for high-dose therapy. However, early discontinuation or treatment modification is often needed owing to adverse events. The aim of this study was to..
101-2501, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea
Tel: +82-2-2271-6792 Fax: +82-2-790-0993 E-mail:
Copyright © 2019 The Korean Association of Internal Medicine. All rights reserved.
For Authors and Reviewers